These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 23272693)

  • 1. Emerging approaches for treatment of schizophrenia: modulation of cholinergic signaling.
    Foster DJ; Jones CK; Conn PJ
    Discov Med; 2012 Dec; 14(79):413-20. PubMed ID: 23272693
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Simultaneous activation of muscarinic and GABA
    Cieślik P; Woźniak M; Tokarski K; Kusek M; Pilc A; Płoska A; Radulska A; Pelikant-Małecka I; Żołnowska B; Sławiński J; Kalinowski L; Wierońska JM
    Behav Brain Res; 2019 Feb; 359():671-685. PubMed ID: 30267715
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selective allosteric modulation of muscarinic acetylcholine receptors for the treatment of schizophrenia and substance use disorders.
    Teal LB; Gould RW; Felts AS; Jones CK
    Adv Pharmacol; 2019; 86():153-196. PubMed ID: 31378251
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Emerging approaches for treatment of schizophrenia: modulation of glutamatergic signaling.
    Noetzel MJ; Jones CK; Conn PJ
    Discov Med; 2012 Nov; 14(78):335-43. PubMed ID: 23200065
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting muscarinic receptors to treat schizophrenia.
    Foster DJ; Bryant ZK; Conn PJ
    Behav Brain Res; 2021 May; 405():113201. PubMed ID: 33647377
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treating schizophrenia: novel targets for the cholinergic system.
    Money TT; Scarr E; Udawela M; Gibbons AS; Jeon WJ; Seo MS; Dean B
    CNS Neurol Disord Drug Targets; 2010 Apr; 9(2):241-56. PubMed ID: 20053170
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TC-5619: an alpha7 neuronal nicotinic receptor-selective agonist that demonstrates efficacy in animal models of the positive and negative symptoms and cognitive dysfunction of schizophrenia.
    Hauser TA; Kucinski A; Jordan KG; Gatto GJ; Wersinger SR; Hesse RA; Stachowiak EK; Stachowiak MK; Papke RL; Lippiello PM; Bencherif M
    Biochem Pharmacol; 2009 Oct; 78(7):803-12. PubMed ID: 19482012
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Cholinergic System: An Emerging Drug Target for Schizophrenia.
    Gibbons A; Dean B
    Curr Pharm Des; 2016; 22(14):2124-33. PubMed ID: 26818859
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of the central cholinergic system in the therapeutics of schizophrenia.
    Terry AV
    Curr Neuropharmacol; 2008 Sep; 6(3):286-92. PubMed ID: 19506725
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activation of M1 and M4 muscarinic receptors as potential treatments for Alzheimer's disease and schizophrenia.
    Foster DJ; Choi DL; Conn PJ; Rook JM
    Neuropsychiatr Dis Treat; 2014; 10():183-91. PubMed ID: 24511233
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Cholinergic hypothesis in psychosis following traumatic brain injury and cholinergic hypothesis in schizophrenia: a link?].
    Bennouna M; Greene VB; Defranoux L
    Encephale; 2007 Sep; 33(4 Pt 1):616-20. PubMed ID: 18033152
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Procognitive effects of varenicline in the animal model of schizophrenia depend on α4β2- and α 7-nicotinic acetylcholine receptors.
    Potasiewicz A; Golebiowska J; Popik P; Nikiforuk A
    J Psychopharmacol; 2018 Dec; 33(1):269881118812097. PubMed ID: 30501536
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Review on Emerging Drug Targets in Treatment of Schizophrenia.
    Ved HS; Doshi GM
    Curr Drug Targets; 2020; 21(15):1593-1605. PubMed ID: 32538726
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alpha7 neuronal nicotinic receptors as targets for novel therapies to treat multiple domains of schizophrenia.
    Kucinski AJ; Stachowiak MK; Wersinger SR; Lippiello PM; Bencherif M
    Curr Pharm Biotechnol; 2011 Mar; 12(3):437-48. PubMed ID: 21133847
    [TBL] [Abstract][Full Text] [Related]  

  • 15. α7 nicotinic acetylcholine receptors as therapeutic targets in schizophrenia: Update on animal and clinical studies and strategies for the future.
    Terry AV; Callahan PM
    Neuropharmacology; 2020 Jun; 170():108053. PubMed ID: 32188568
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Muscarinic agonists and antagonists in schizophrenia: recent therapeutic advances and future directions.
    Bolbecker AR; Shekhar A
    Handb Exp Pharmacol; 2012; (208):167-90. PubMed ID: 22222699
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of Nicotinic and Muscarinic Receptors on Synaptic Plasticity and Neurological Diseases.
    Fuenzalida M; Pérez MÁ; Arias HR
    Curr Pharm Des; 2016; 22(14):2004-14. PubMed ID: 26818867
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Muscarinic and nicotinic acetylcholine receptor agonists: current scenario in Alzheimer's disease therapy.
    Verma S; Kumar A; Tripathi T; Kumar A
    J Pharm Pharmacol; 2018 Aug; 70(8):985-993. PubMed ID: 29663387
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular mechanisms of synergy of corneal muscarinic and nicotinic acetylcholine receptors in upregulation of E-cadherin expression.
    Chernyavsky AI; Galitovskiy V; Grando SA
    Int Immunopharmacol; 2015 Nov; 29(1):15-20. PubMed ID: 25957200
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treating schizophrenia symptoms with an alpha7 nicotinic agonist, from mice to men.
    Olincy A; Stevens KE
    Biochem Pharmacol; 2007 Oct; 74(8):1192-201. PubMed ID: 17714692
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.